You are here

  • Home
  • Archive
  • Volume 9, Issue 6
  • Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial

 

Online download statistics by month:

Online download statistics by month: June 2021 to March 2026

AbstractFullPdf
Jun 202115515567
Jul 2021292293121
Aug 202119719770
Sep 202113013055
Oct 202118618667
Nov 202114514560
Dec 202110410632
Jan 202212313258
Feb 2022969633
Mar 202212513367
Apr 202211912463
May 202211612467
Jun 202212413449
Jul 202213514340
Aug 202212012637
Sep 202214715448
Oct 202211311756
Nov 202213413452
Dec 20229910037
Jan 202311211328
Feb 202316516639
Mar 2023949952
Apr 2023626333
May 2023909135
Jun 202311611742
Jul 202310310860
Aug 202310510962
Sep 2023909031
Oct 2023878832
Nov 202311111852
Dec 2023595937
Jan 2024636552
Feb 202410911058
Mar 2024107107108
Apr 2024858681
May 202411511667
Jun 202412512444
Jul 202410710847
Aug 2024606137
Sep 2024848440
Oct 202411411653
Nov 202410911153
Dec 202419419876
Jan 202510510665
Feb 202513913960
Mar 202511411552
Apr 202515115179
May 2025727261
Jun 2025777827
Jul 2025220
Aug 2025110
Feb 2026110
Mar 2026110
Total578959022642